Market ExpansionThe expansion to CKD is a significant market opportunity and expands Furoscix’s prescriber base to nephrologists.
Product Launch SuccessFuroscix launched promotional efforts for Chronic Kidney Disease and is being positively received, with progress faster than the initial heart failure launch.
Revenue GrowthScPharmaceuticals reported 1Q25 results with revenue of $11.8M, up 92.6% year-over-year, beating consensus and estimates.